News! Medical Greens Announces a New Addition to t
Post# of 36728
Posted On: 11/06/2013 4:24:19 PM
News! Medical Greens Announces a New Addition to the Dharmanol™ Product Line, Dharmanol Citrolene
SOURCE: SK3 Group, Inc.
November 06, 2013 16:11 ET
Medical Greens Announces a New Addition to the Dharmanol™ Product Line, Dharmanol Citrolene, During November 5th Conference Call
LOS ANGELES, CA--(Marketwired - Nov 6, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) (the "Company") through Mr. David Hoye, developer of the Dharmanol™ product line for Berkeley Bio-organic Research Laboratories, announced a new product line Dharmanol™ Citrolene. The conference call can be heard on the Company's web site, http://www.medicalgreens.com
Mr. Hoye noted the following: "D-Limonene is one of the most important terpenes found in cannabis/hemp. It has shown significant anti-cancer properties in a number of studies." Sloan Kettering Cancer Institute says: "Animal studies show activity of D-limonene against pancreatic, stomach, colon, skin, and liver cancers. Data also indicate that D-limonene slows the promotion/progression stage of carcinogen-induced tumors in rats. The chemopreventive activity of D-limonene may be via inhibition of inflammation, oxidative stress and Ras-signaling as well as the induction of pro-apoptotic state in a mouse model of skin tumorigenesis."
There are a number of studies showing possible efficacy of D-limonene against various forms of cancer, utilizing various mechanisms. 18 of these studies can be found on the Sloan-Kettering website, which is here: http://www.mskcc.org/cancer-care/herb/d-limonene
Along with many studies on treating cancer with D-limonene, other studies have shown that the molecule attaches to the same receptor sites in humans as benzodiazepines such as Valium and Xanax. It is suggested that D-limonene stimulates these sites in the same manner that cannabis stimulates the Anandamide receptors in the human body. Because the relaxing and depressive effects of Valium and Xanax are well known, it is thought that natural chemicals stimulating the same receptors will have similar actions, but with greatly reduced toxicity.
D-Limonene is thought to be responsible for much of the relaxing effects of smoked cannabis. These effects are often absent in refined cannabinoid extracts which have many of the elements of the plant removed.
A substantial dose of D-limonene is present in Dharmanol Citrolene. When combined with the CBD, mixed cannabinoid carboxylates, and the steam-extracted terpene mixture that comprises the basic Dharmanol formula, D-limonene helps to provide much of the synergistic "whole plant" effect that many patients have found to be far superior to refined preparations where many of the essential elements of the plant are removed and discarded.
Mr. Hoye concluded, "While the cannabinoids are only to be found in marijuana / hemp, many of the terpenes are found in a wide variety of different plants. The D-limonene in Dharmanol ™ is identical to that in all varieties of cannabis, but is sourced from other plants. There is 250 mg. of food-grade D-limonene in every tablet."
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
About SK3 Group, Inc.
SK3 Group, Inc. is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, the Company brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
SK3 Group, Inc.
investors@medicalgreens.com
Or call 855-868-7577 (Dial 1 for direct IR)
http://www.marketwired.com/press-release/medi...849312.htm
SOURCE: SK3 Group, Inc.
November 06, 2013 16:11 ET
Medical Greens Announces a New Addition to the Dharmanol™ Product Line, Dharmanol Citrolene, During November 5th Conference Call
LOS ANGELES, CA--(Marketwired - Nov 6, 2013) - SK3 Group, Inc.'s (OTC Pink: SKTO) (the "Company") through Mr. David Hoye, developer of the Dharmanol™ product line for Berkeley Bio-organic Research Laboratories, announced a new product line Dharmanol™ Citrolene. The conference call can be heard on the Company's web site, http://www.medicalgreens.com
Mr. Hoye noted the following: "D-Limonene is one of the most important terpenes found in cannabis/hemp. It has shown significant anti-cancer properties in a number of studies." Sloan Kettering Cancer Institute says: "Animal studies show activity of D-limonene against pancreatic, stomach, colon, skin, and liver cancers. Data also indicate that D-limonene slows the promotion/progression stage of carcinogen-induced tumors in rats. The chemopreventive activity of D-limonene may be via inhibition of inflammation, oxidative stress and Ras-signaling as well as the induction of pro-apoptotic state in a mouse model of skin tumorigenesis."
There are a number of studies showing possible efficacy of D-limonene against various forms of cancer, utilizing various mechanisms. 18 of these studies can be found on the Sloan-Kettering website, which is here: http://www.mskcc.org/cancer-care/herb/d-limonene
Along with many studies on treating cancer with D-limonene, other studies have shown that the molecule attaches to the same receptor sites in humans as benzodiazepines such as Valium and Xanax. It is suggested that D-limonene stimulates these sites in the same manner that cannabis stimulates the Anandamide receptors in the human body. Because the relaxing and depressive effects of Valium and Xanax are well known, it is thought that natural chemicals stimulating the same receptors will have similar actions, but with greatly reduced toxicity.
D-Limonene is thought to be responsible for much of the relaxing effects of smoked cannabis. These effects are often absent in refined cannabinoid extracts which have many of the elements of the plant removed.
A substantial dose of D-limonene is present in Dharmanol Citrolene. When combined with the CBD, mixed cannabinoid carboxylates, and the steam-extracted terpene mixture that comprises the basic Dharmanol formula, D-limonene helps to provide much of the synergistic "whole plant" effect that many patients have found to be far superior to refined preparations where many of the essential elements of the plant are removed and discarded.
Mr. Hoye concluded, "While the cannabinoids are only to be found in marijuana / hemp, many of the terpenes are found in a wide variety of different plants. The D-limonene in Dharmanol ™ is identical to that in all varieties of cannabis, but is sourced from other plants. There is 250 mg. of food-grade D-limonene in every tablet."
FDA Disclaimer
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. Use only as directed.
About SK3 Group, Inc.
SK3 Group, Inc. is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, the Company brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
SK3 Group, Inc.
investors@medicalgreens.com
Or call 855-868-7577 (Dial 1 for direct IR)
http://www.marketwired.com/press-release/medi...849312.htm
(0)
(0)SK3 Group Inc. (SKTO) Stock Research Links
Scroll down for more posts ▼